BioCapital
Filter News
Found 35,834 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
OpGen, Inc. Announces Notice of Annual Meeting Venue Change
9/18/2020
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) announced today that it has changed the venue of its 2020 Annual Meeting of Stockholders due to continuing health and safety considerations arising from the COVID-19 pandemic.
-
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
9/18/2020
CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent: European Patent 2989121 to be published on October 7, 2020, and titled “Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis” for the Company’s LEAPS platform technology.
-
Foundation for the NIH Honors Anthony S. Fauci, M.D., with the 5th Charles A. Sanders, M.D., Partnership Award
9/18/2020
The Foundation for the National Institutes of Health (FNIH) is honored to announce Anthony S. Fauci , M.D., as the recipient of the 2020 Charles A. Sanders, M.D., Partnership Award. The award, now in its fifth year, recognizes persons and/or organizations that have made significant contributions to the FNIH's work to build
-
Foundation for the NIH Awards 2020 Trailblazer Prize for Clinician-Scientists to Michael Wilson, M.D.
9/18/2020
The Foundation for the National Institutes of Health (FNIH) today bestowed its annual Trailblazer Prize for Clinician-Scientists to Michael Wilson , M.D., of the University of California San Francisco (UCSF). Dr. Wilson has received the Trailblazer Prize, along with a $10,000 honorarium, for pioneering a next-generat
-
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Non-small Cell Lung Cancer With an Estimated 50% of Patients Surviving Four Years
9/18/2020
PACIFIC Phase III trial data at ESMO also showed an estimated 35% of non-small cell lung cancer patients treated with IMFINZI® had not progressed after four years
-
LYNPARZA® (olaparib) Improved Median Time Patients Lived Without Disease Progression to Over Four and Half Years in BRCA-mutated Advanced Ovarian Cancer vs. Just Over One Year With Placebo
9/18/2020
Five-year data from the SOLO-1 Phase III trial is the longest follow-up analysis for any PARP inhibitor in the 1st-line maintenance setting
-
Sensei Biotherapeutics Reports Early Data from Phase 1/2 Clinical Trial of SNS-301 in Combination with Pembrolizumab in Advanced Head and Neck Cancer Patients at ESMO 2020
9/18/2020
Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, announced today results from the Phase 1/2 clinical trial evaluating the safety, efficacy, and immunogenicity of SNS‑301, a first-in-class bio-engineered, inactivated bacteriophage, in patients with Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
-
Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
9/18/2020
Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate
-
National Association of Specialty Pharmacy (NASP) Inducted New Chairman of the Board and Announced Scholarship, NASP Challenge and Abstract Award Recipients During the 2020 Annual Meeting & Expo Virtual Experience
9/18/2020
National Association of Specialty Pharmacy (NASP) shined the spotlight on the NASP Ron Bookman Memorial Scholarship recipients, the very first NASP Innovation Challenge winner and Abstract/Poster award winners during the 2020 Annual Meeting & Expo Virtual Experience
-
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal
9/18/2020
Independent central review confirmed responses include 1 complete response, 12 partial responses and 33 stable disease for an objective response rate of 14% and disease control rate of 49%
-
Robert Redfield, director of the U.S. Centers for Disease Control and Prevention, testified yesterday before the U.S. Senate Appropriations subcommittee on labor, health and human services, education and related agencies.
-
Real Time Medical Systems Appoints Steven M. Stein, MD as Chief Medical Officer
9/17/2020
Real Time Medical Systems (Real Time), the leading post-acute interventional analytics platform, today announced the appointment of Steven M. Stein, MD as Chief Medical Officer.
-
Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
9/17/2020
Incyte (Nasdaq:INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that the companies intend to host a conference call and webcast to discuss global development, unmet need and commercial opportunities for tafasitamab.
-
The American Nurses Association and Rita Wilson Launch "The Race to 200M," a National Program to Increase Urgency of Flu Vaccinations Among Those Most Vulnerable to Influenza and Its Complications
9/17/2020
Flu vaccination is especially important for people who are most at risk of flu complications, namely the 200 million people over the age of 50 and individuals who have chronic health conditions
-
GORE PHASEFLEX Microwave/RF Test Assemblies Honored, Set Gold Standard With Industry Innovators Award
9/17/2020
W. L. Gore & Associates announced today that its GORE® PHASEFLEX® Microwave/RF Test Assemblies were recognized among the 2020 Military & Aerospace Electronics Innovators Awards.
-
Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19
9/17/2020
Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the patented One-component Self-Assembling protein NanoParticle® (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), announced the advancement toward Phase I clinical trials of its next-generation SARS-CoV-2
-
Bio-Process Systems Alliance Releases 2020 Extractables/Leachables Guide
9/17/2020
The Bio-Process Systems Alliance (BPSA), the international association of the single-use bio-processing industry, is pleased to announce the release of its latest 2020 technical guide: Extractables/Lea